Anthony C Becker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anthony C Becker has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Karen Sliwa
Cape Heart Institute, Faculty of Health Sciences, University of Cape Town , Cape Town
3 shared publications - Simon Stewart
School of Medicine, The University of Notre Dame, Fremantle, Western Australia, Australia
3 shared publications E. Libhaber
Division of Cardiology, Chris Hani Baragwanath Hospital, Johannesburg, South Africa, University of the Witwatersrand, Johannesburg, South Africa
2 shared publicationsM.R. Essop
Division of Cardiology, Chris Hani Baragwanath Hospital, Johannesburg, South Africa, University of the Witwatersrand, Johannesburg, South Africa
2 shared publicationsA.R. Essop
1 shared publicationB. Jacobson
National Health Laboratory Service, School of Pathology, Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa
1 shared publication
Latest Publications
- Open Access
- 4 October 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 379
Antiphospholipid antibodies in black south africans with hiv and acute coronary syndromes: prevalence and clinical correlates
HIV infection is associated with a high prevalence of antiphospholipid antibodies (aPL) and increased thrombotic events but the aetiopathogenic link between the two is unclear.
- 4 October 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 379
Open AccessAntiphospholipid antibodies in black south africans with hiv and acute coronary syndromes: prevalence and clinical correlates
HIV infection is associated with a high prevalence of antiphospholipid antibodies (aPL) and increased thrombotic events but the aetiopathogenic link between the two is unclear.
- Open Access
- 11 May 2010
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 17 (3) , 264-272
The Thrombotic Profile of Treatment-Naive HIV-Positive Black South Africans With Acute Coronary Syndromes
Background: Patients with human immunodeficiency virus (HIV) infection on protease inhibitors (PIs) have a heightened risk of arterial thrombosis but little is known about treatment-naive patients. Methods/Results: Prospective study from South Africa comparing thrombotic profiles of HIV-positive and -negative patients with acute coronary syndrome (ACS). A total of 30 treatment-naive HIV-positive patients with ACS were compared to 30 HIV-negative patients with ACS. Patients with HIV were younger; and besides smoking (73% vs 33%) and low high-density lipoprotein (HDL; 0.8 ± 0.3 vs 1.1 ± 0.4), they had fewer risk factors. Thrombophilia was more common in HIV-positive patients with lower protein C (PC; 82 ± 22 vs 108 ± 20) and higher factor VIII levels (201 ± 87 vs 136 ± 45). Patients with HIV had higher frequencies of anticardiolipin (aCL; 47% vs 10%) and antiprothrombin antibodies (87% vs 21%). Conclusion: Treatment-naive HIV-positive patients with ACS are younger, with fewer traditional risk factors but a greater degree of thrombophilia compared with HIV-negative patients.
- 11 May 2010
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 17 (3) , 264-272
Open AccessThe Thrombotic Profile of Treatment-Naive HIV-Positive Black South Africans With Acute Coronary Syndromes
Background: Patients with human immunodeficiency virus (HIV) infection on protease inhibitors (PIs) have a heightened risk of arterial thrombosis but little is known about treatment-naive patients. Methods/Results: Prospective study from South Africa comparing thrombotic profiles of HIV-positive and -negative patients with acute coronary syndrome (ACS). A total of 30 treatment-naive HIV-positive patients with ACS were compared to 30 HIV-negative patients with ACS. Patients with HIV were younger; and besides smoking (73% vs 33%) and low high-density lipoprotein (HDL; 0.8 ± 0.3 vs 1.1 ± 0.4), they had fewer risk factors. Thrombophilia was more common in HIV-positive patients with lower protein C (PC; 82 ± 22 vs 108 ± 20) and higher factor VIII levels (201 ± 87 vs 136 ± 45). Patients with HIV had higher frequencies of anticardiolipin (aCL; 47% vs 10%) and antiprothrombin antibodies (87% vs 21%). Conclusion: Treatment-naive HIV-positive patients with ACS are younger, with fewer traditional risk factors but a greater degree of thrombophilia compared with HIV-negative patients.
- 2 February 2010
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 23 (1) , 70-77
Acute Coronary Syndromes in Treatment‐Naïve Black South Africans with Human Immunodeficiency Virus Infection
Background: HIV patients on protease inhibitors have greater risk of acute coronary syndromes (ACS) but little is known about treatment‐naïve patients. Methods and Results: Authors conducted a prospective single‐center study from Soweto, South Africa, comparing the clinical and angiographic features of treatment‐naïve HIV positive and negative patients with ACS. Between March 2004 and February 2008, 30 consecutive treatment‐naïve HIV patients with ACS were compared to the next HIV‐negative patient as a 1:1 control. HIV patients were younger (43 ± 7 vs. 54 ± 13, P = 0.004) and, besides smoking (73% vs. 33%, P = 0.002), had fewer risk factors than the control group with less hypertension (23% vs. 77%, P = 0.0001), diabetes (3% vs. 23%, P = 0.05), LDL hyperlipidemia (2.2 ± 0.9 vs. 3.0 ± 1.2, P = 0.006), and other coronary risk factors (7% vs. 53%, P = 0.0001). HDL was lower in the HIV group (0.8 ± 0.3 vs. 1.1 ± 0.4, P = 0.001). Atherosclerotic burden was lower in the HIV group with more normal infarct‐related arteries (47% vs. 13%, P = 0.005) but a higher degree of large thrombus burden (43% vs. 17%, P = 0.02). Stents were used to a similar degree in HIV and control patients (30% vs. 37%, P = 0.78) with more target lesion revascularization in the HIV group (56% vs. 0%, P = 0.008). Conclusion: Treatment‐naïve HIV patients with ACS are younger and have fewer traditional risk factors than HIV‐negative patients. HIV patients have less atherosclerotic but higher thrombotic burden which may imply a prothrombotic state in the pathogenesis of ACS in these patients. (J Interven Cardiol 2010;23:70–77)
- 2 February 2010
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 23 (1) , 70-77
Acute Coronary Syndromes in Treatment‐Naïve Black South Africans with Human Immunodeficiency Virus Infection
Background: HIV patients on protease inhibitors have greater risk of acute coronary syndromes (ACS) but little is known about treatment‐naïve patients. Methods and Results: Authors conducted a prospective single‐center study from Soweto, South Africa, comparing the clinical and angiographic features of treatment‐naïve HIV positive and negative patients with ACS. Between March 2004 and February 2008, 30 consecutive treatment‐naïve HIV patients with ACS were compared to the next HIV‐negative patient as a 1:1 control. HIV patients were younger (43 ± 7 vs. 54 ± 13, P = 0.004) and, besides smoking (73% vs. 33%, P = 0.002), had fewer risk factors than the control group with less hypertension (23% vs. 77%, P = 0.0001), diabetes (3% vs. 23%, P = 0.05), LDL hyperlipidemia (2.2 ± 0.9 vs. 3.0 ± 1.2, P = 0.006), and other coronary risk factors (7% vs. 53%, P = 0.0001). HDL was lower in the HIV group (0.8 ± 0.3 vs. 1.1 ± 0.4, P = 0.001). Atherosclerotic burden was lower in the HIV group with more normal infarct‐related arteries (47% vs. 13%, P = 0.005) but a higher degree of large thrombus burden (43% vs. 17%, P = 0.02). Stents were used to a similar degree in HIV and control patients (30% vs. 37%, P = 0.78) with more target lesion revascularization in the HIV group (56% vs. 0%, P = 0.008). Conclusion: Treatment‐naïve HIV patients with ACS are younger and have fewer traditional risk factors than HIV‐negative patients. HIV patients have less atherosclerotic but higher thrombotic burden which may imply a prothrombotic state in the pathogenesis of ACS in these patients. (J Interven Cardiol 2010;23:70–77)